Total Payments
$440,956
2024 Payments
$21,039
Companies
15
Transactions
475
Payment Breakdown by Category
Other$316,455 (71.8%)
Travel$60,316 (13.7%)
Consulting$53,635 (12.2%)
Food & Beverage$10,429 (2.4%)
Research$121.01 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $258,205 | 88 | 58.6% |
| Travel and Lodging | $60,316 | 187 | 13.7% |
| Consulting Fee | $53,635 | 14 | 12.2% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $36,000 | 10 | 8.2% |
| Honoraria | $16,970 | 15 | 3.8% |
| Food and Beverage | $10,429 | 156 | 2.4% |
| Compensation for serving as faculty or as a speaker for a medical education program | $5,280 | 3 | 1.2% |
| Unspecified | $121.01 | 2 | 0.0% |
Payments by Type
General
$440,835
473 transactions
Research
$121.01
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Gilead Sciences, Inc. | $229,463 | 254 | $0 (2023) |
| Merck Sharp & Dohme Corporation | $92,402 | 97 | $0 (2018) |
| INTERCEPT PHARMACEUTICALS, INC. | $44,713 | 53 | $0 (2023) |
| Shire North American Group Inc | $15,398 | 6 | $0 (2018) |
| Valeant Pharmaceuticals North America LLC | $15,353 | 18 | $0 (2017) |
| Madrigal Pharmaceuticals | $11,313 | 14 | $0 (2024) |
| Mallinckrodt LLC | $10,480 | 2 | $0 (2018) |
| Ipsen Bioscience Inc. | $9,690 | 1 | $0 (2024) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $6,219 | 8 | $0 (2024) |
| Dova Pharmaceuticals | $4,488 | 5 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $21,039 | 17 | Madrigal Pharmaceuticals ($11,313) |
| 2023 | $9,829 | 14 | Gilead Sciences, Inc. ($8,589) |
| 2022 | $16,370 | 18 | Gilead Sciences, Inc. ($11,050) |
| 2021 | $11,925 | 12 | Gilead Sciences, Inc. ($7,495) |
| 2020 | $15,098 | 18 | Gilead Sciences, Inc. ($12,623) |
| 2019 | $50,369 | 53 | Gilead Sciences, Inc. ($40,629) |
| 2018 | $128,245 | 120 | Gilead Sciences, Inc. ($72,289) |
| 2017 | $188,081 | 223 | Merck Sharp & Dohme Corporation ($78,497) |
All Payment Transactions
475 individual payment records from CMS Open Payments — Page 19 of 19
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 02/20/2017 | Gilead Sciences Inc | Epclusa (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,500.00 | General |
| Category: HCV | ||||||
| 02/16/2017 | Gilead Sciences Inc | Epclusa (Drug) | Travel and Lodging | In-kind items and services | $831.51 | General |
| Category: HCV | ||||||
| 02/16/2017 | Gilead Sciences Inc | Epclusa (Drug) | Travel and Lodging | In-kind items and services | $414.40 | General |
| Category: HCV | ||||||
| 02/16/2017 | Gilead Sciences Inc | Epclusa (Drug) | Travel and Lodging | In-kind items and services | $234.93 | General |
| Category: HCV | ||||||
| 02/16/2017 | Gilead Sciences Inc | Epclusa (Drug) | Food and Beverage | In-kind items and services | $103.25 | General |
| Category: HCV | ||||||
| 02/15/2017 | Merck Sharp & Dohme Corporation | ZEPATIER (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,500.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 02/14/2017 | Valeant Pharmaceuticals North America LLC | XIFAXAN (Drug) | Travel and Lodging | Cash or cash equivalent | $581.11 | General |
| Category: GASTROENTEROLOGY | ||||||
| 02/14/2017 | Valeant Pharmaceuticals North America LLC | XIFAXAN (Drug) | Travel and Lodging | Cash or cash equivalent | $329.40 | General |
| Category: GASTROENTEROLOGY | ||||||
| 02/09/2017 | Merck Sharp & Dohme Corporation | ZEPATIER (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,500.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 02/09/2017 | Merck Sharp & Dohme Corporation | ZEPATIER (Drug) | Travel and Lodging | In-kind items and services | $868.36 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 02/09/2017 | Merck Sharp & Dohme Corporation | ZEPATIER (Drug) | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 02/09/2017 | Merck Sharp & Dohme Corporation | ZEPATIER (Drug) | Food and Beverage | In-kind items and services | $117.96 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 02/07/2017 | Valeant Pharmaceuticals North America LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $10.69 | General |
| Category: GASTROENTEROLOGY | ||||||
| 02/02/2017 | Merck Sharp & Dohme Corporation | ZEPATIER (Drug) | Travel and Lodging | In-kind items and services | $484.64 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 02/02/2017 | Merck Sharp & Dohme Corporation | ZEPATIER (Drug) | Travel and Lodging | In-kind items and services | $388.06 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 02/02/2017 | Merck Sharp & Dohme Corporation | ZEPATIER (Drug) | Travel and Lodging | In-kind items and services | $130.30 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 01/26/2017 | Gilead Sciences Inc | Epclusa (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,500.00 | General |
| Category: HCV | ||||||
| 01/26/2017 | Gilead Sciences Inc | Epclusa (Drug) | Travel and Lodging | In-kind items and services | $22.47 | General |
| Category: HCV | ||||||
| 01/26/2017 | AbbVie, Inc. | Viekira (Drug) | Food and Beverage | In-kind items and services | $22.07 | General |
| Category: Virology | ||||||
| 01/24/2017 | Gilead Sciences Inc | Epclusa (Drug) | Travel and Lodging | In-kind items and services | $772.20 | General |
| Category: HCV | ||||||
| 01/24/2017 | Gilead Sciences Inc | Epclusa (Drug) | Travel and Lodging | In-kind items and services | $302.40 | General |
| Category: HCV | ||||||
| 01/24/2017 | Gilead Sciences Inc | Epclusa (Drug) | Travel and Lodging | In-kind items and services | $170.24 | General |
| Category: HCV | ||||||
| 01/24/2017 | Gilead Sciences Inc | Epclusa (Drug) | Food and Beverage | In-kind items and services | $116.69 | General |
| Category: HCV | ||||||
| 01/19/2017 | Intercept Pharmaceuticals, Inc. | OCA (Drug) | Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | Cash or cash equivalent | $3,400.00 | General |
| Category: Gastroenterology | ||||||
| 01/19/2017 | Intercept Pharmaceuticals, Inc. | OCA (Drug) | Food and Beverage | In-kind items and services | $124.14 | General |
| Category: Gastroenterology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| NN9535-4321 | Novo Nordisk AS | $121.01 | 2 |
About Dr. Norman Gitlin, MD
Dr. Norman Gitlin, MD is a Gastroenterology healthcare provider based in Atlanta, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/31/2005. The National Provider Identifier (NPI) number assigned to this provider is 1669463543.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Norman Gitlin, MD has received a total of $440,956 in payments from pharmaceutical and medical device companies, with $21,039 received in 2024. These payments were reported across 475 transactions from 15 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($258,205).
Ad
Practice Information
- Specialty Gastroenterology
- Location Atlanta, GA
- Active Since 10/31/2005
- Last Updated 07/21/2011
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1669463543
Products in Payments
- Epclusa (Drug) $162,811
- ZEPATIER (Drug) $61,143
- Vemlidy (Drug) $42,651
- OCALIVA (Drug) $27,448
- XIFAXAN (Drug) $21,549
- OCA (Drug) $17,265
- REZDIFFRA (Drug) $11,313
- Vosevi (Drug) $4,925
- Doptelet (Drug) $4,488
- Mulpleta (Drug) $750.00
- Mavyret (Drug) $149.22
- Viekira (Drug) $74.04
- UCERIS TABLETS (Drug) $22.88
- CUVRIOR (Drug) $17.15
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Atlanta
Douglas Wolf, Md, MD
Gastroenterology — Payments: $893,748
Gastroenterology $893,748
Enrique Martinez, Md, MD
Gastroenterology — Payments: $691,094
Gastroenterology $691,094
Dr. Kavita Kongara, M.d, M.D
Gastroenterology — Payments: $576,854
Gastroenterology $576,854
Girish Anand, M.d, M.D
Gastroenterology — Payments: $482,731
Gastroenterology $482,731
Dr. Hetal Karsan, Md, MD
Gastroenterology — Payments: $371,430
Gastroenterology $371,430
Dr. Marc Sonenshine, Md, MD
Gastroenterology — Payments: $311,059
Gastroenterology $311,059